<div id="readability-page-1"><p>Evogene Ltd. ((EVGN)) has held its Q4 earnings call. Read on for the main highlights of the call.</p><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Evogene’s latest earnings call painted a mixed picture, blending ambitious technological progress with clear financial strain. Management emphasized a successful strategic refocus and sharp cost cuts, yet investors also heard about falling revenues, large inventory impairments and a thinner cash cushion that depends on future deals and distributions to sustain operations.</p> <h2>Strategic Refocus on ChemPass AI and Core Markets</h2> <p>Evogene has completed a sweeping strategic overhaul to center the company on a single engine, ChemPass AI, and two end markets. The focus is now squarely on small‑molecule drugs and agricultural chemicals, with noncore assets divested and business development realigned around this streamlined vision.</p> <h2>Platform Scale and Technical Milestones</h2> <p>ChemPass AI is built on a foundation model trained across a universe of 38 billion molecules, giving Evogene broad reach into chemical space from the outset. The first collaboration on Google Cloud, completed in mid‑2025, reportedly reached about 90% design precision, a threefold improvement over existing benchmarks.</p> <h2>Automation Push with Google Cloud</h2> <p>In February 2026, Evogene launched a second collaboration with Google Cloud to integrate Vertex AI agents into ChemPass workflows. The goal is to automate complex discovery steps, cut manual errors and move toward autonomous R&amp;D that can scale across pharma and ag‑chem partnerships.</p> <h2>Growing Partnerships and Early Commercial Traction</h2> <p>The company highlighted four publicly disclosed collaborations in human health and strategic agriculture ties with Bayer and Corteva. Management expects these partnered discovery programs to ramp through 2026, potentially translating ChemPass capabilities into milestone‑driven and recurring revenue streams.</p> <h2>Substantial Reductions in Operating Expenses</h2> <p>Evogene’s cost base has shrunk materially, with total net operating expenses dropping to about $13.8 million in 2025 from roughly $22 million a year earlier. Fourth‑quarter operating expenses also fell to around $3.2 million from $4.3 million, and management signaled that this leaner structure should persist.</p> <h2>R&amp;D, Sales and Administrative Costs Move Lower</h2> <p>Research and development spending net declined to about $8 million from $12.5 million, reflecting the narrower focus and efficiency drive. Sales and marketing slipped to roughly $1.5 million and general and administrative costs fell to about $4.3 million, marking reductions of roughly a quarter to nearly 40%.</p> <h2>Improved Annual Operating and Net Loss</h2> <p>The full‑year operating loss improved to around $14 million from $18.8 million, helped by the expense cuts. Net loss narrowed more sharply, to about $7.8 million versus $18.1 million, aided by gains from discontinued operations that masked some of the underlying operating weakness.</p> <h2>Cash Position and Near‑Term Financing Actions</h2> <p>Evogene ended 2025 with approximately $13 million in cash, cash equivalents and short‑term deposits, after using around $3 million in the fourth quarter. A February 2026 warrant inducement added roughly $3.4 million in gross proceeds, while expected distributions from affiliates are seen extending cash runway to about a year and a half.</p> <h2>Revenue Contraction and Q4 Collapse</h2> <p>On the top line, performance deteriorated, with 2025 revenue slipping to about $3.9 million from $5.6 million a year earlier. The pressure was most acute in the fourth quarter, when revenue plunged to roughly $0.3 million from $1.5 million, mainly due to lower seed sales at AgPlenus and Casterra and fewer one‑off payments.</p> <h2>Inventory Impairment Drives Higher Cost of Revenues</h2> <p>Despite weaker sales, cost of revenues jumped to approximately $4.1 million in 2025 from $2.4 million, driven largely by a roughly $2.2 million Casterra inventory impairment booked in the fourth quarter. Q4 cost of revenues surged to about $2.3 million from $0.7 million, intensifying margin pressure.</p> <h2>Quarterly Losses Worsen in Late 2025</h2> <p>The company’s quarterly profitability profile worsened, with Q4 2025 operating loss widening to around $5.2 million from $3.5 million in the prior‑year period. Net loss in the quarter spiked to about $5.4 million compared with a near breakeven result previously, reflecting the revenue decline, higher costs and weaker financing income.</p> <h2>Sharp Drop in Financing Income</h2> <p>Financing income net slumped to roughly $0.6 million in 2025 from $4 million in 2024 due in part to changes in accounting for warrants. The fourth quarter flipped from about $4.5 million of financing income a year earlier to roughly $0.2 million of net financing expense, removing a key cushion to the bottom line.</p> <h2>Seed Business Retrenchment and Market Weakness</h2> <p>Evogene’s Casterra unit ceased operations in Kenya after a steep decline in demand for castor seeds, refocusing on Brazil with a reduced headcount. The pullback led to the roughly $2.2 million inventory impairment and a drop in seed sales that weighed heavily on both revenue and cost of sales.</p> <h2>Dependence on Discontinued Operations and Asset Sales</h2> <p>Income from discontinued operations swung to about $5.7 million in 2025 from a loss of roughly $3.2 million in 2024, largely due to gains on asset sales. Management stressed that these proceeds boosted reported net results, but investors should view them as one‑time rather than indicative of ongoing business strength.</p> <h2>Modest Cash and Runway Constraints</h2> <p>With around $13 million in cash and a quarterly burn rate near $2.4 million excluding affiliates, Evogene’s financial runway remains modest. The company believes its resources, plus expected distributions, can fund it to at least mid‑next year, but further deals or financing will be needed to extend beyond that horizon.</p> <h2>Guidance and Outlook</h2> <p>Looking ahead, management expects the lower cost base, including about $13.8 million of annual operating expenses, to hold while ChemPass AI becomes the primary growth engine. They pointed to the platform’s 38‑billion‑molecule training set and high design precision as catalysts for deeper pharma and ag‑chem collaborations, even as current revenue and cash levels keep execution risk elevated.</p> <p>Evogene’s earnings call left investors weighing a powerful AI‑driven discovery story against a fragile financial foundation. If the company can convert its technology and partnerships into durable revenue while keeping costs in check, the refocused model could gain traction, but near‑term volatility and funding needs remain central risks to monitor.</p></div>

SBIO

<p>Evogene Ltd. held its Q4 earnings call, revealing a mixed outlook with ambitious AI developments but significant financial challenges. The company has streamlined its focus on ChemPass AI and core markets, resulting in substantial cost reductions. However, revenues fell sharply, with Q4 revenue dropping to $0.3 million from $1.5 million, largely due to lower seed sales. Operating losses widened in Q4, and cash reserves are under pressure, necessitating future financing to sustain operations. Despite these challenges, Evogene is pursuing partnerships and automation to drive future growth.</p>

Evogene Earnings Call: AI Ambition Meets Cash Reality